Back
Kymera Therapeutics Quote, Financials, Valuation and Earnings
The Biggest Financial Event of 2024?
Click here to find out.
Buy
54
KYMR
Kymera Therapeutics
Last Price:
45.39
Seasonality Move:
17.96%
7 Day Trial
ALL ACCESS PASS
$
7
1-day winners in this choppy market
Get the 1-day winners strategy here.Kymera Therapeutics Price Quote
$45.39
-0.01 (-2.6%)
(Updated: September 7, 2024 at 6:41 AM ET)
Kymera Therapeutics Key Stats
Buy
54
Kymera Therapeutics (KYMR)
is a Buy
Day range:
$43.90 - $48.53
52-week range:
$9.60 - $50.19
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
33.43
P/B ratio:
4.09%
Volume:
184K
Avg. volume:
424.5K
1-year change:
136.83%
Market cap:
$2.8B
Revenue:
$78.6M
EPS:
$-2.42
How Much Does Kymera Therapeutics Make?
-
How Much Are Kymera Therapeutics's Sales Annually?
KYMR Revenues are $78.6M -
How Much Profit Does Kymera Therapeutics's Make A Year?
KYMR net income is -$147M
Is Kymera Therapeutics Growing As A Company?
-
What Is Kymera Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.55% -
What Is Kymera Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Kymera Therapeutics Stock Price Performance
-
Did Kymera Therapeutics Stock Go Up Last Month?
Kymera Therapeutics share price went up by 9.61% last month -
Did KYMR's Share Price Rise Over The Last Year?
KYMR share price rose by 136.83% over the past 1 year
What Is Kymera Therapeutics 52-Week High & Low?
-
What Is Kymera Therapeutics’s 52-Week High Share Price?
Kymera Therapeutics has traded as high as $50.19 over the past 52 weeks -
What Is Kymera Therapeutics’s 52-Week Low Share Price?
Kymera Therapeutics has traded as low as $9.60 over the past 52 weeks
Kymera Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Kymera Therapeutics?
-
How Much Debt Does Kymera Therapeutics Have?
Total long term debt quarterly is $0 -
How Much Cash Does Kymera Therapeutics Have?
Cash and short term investments quarterly total is $510M -
What Is Kymera Therapeutics’s Book Value Per Share?
Book value per share is 11.12
Is Kymera Therapeutics Cash Flow Positive?
-
What Is KYMR Cash Flow From Operations?
Cash flow from operations (TTM) is -$106.1M -
What Is Kymera Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $356.9M -
What Is Kymera Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$235.5M
Kymera Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
KYMR return on invested capital is -30.1% -
What Is Kymera Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -23.18% -
What Is KYMR Return On Equity?
ROE is a measure of profitability and is -30.1%
Kymera Therapeutics Earnings Date & Stock Price
-
What Is Kymera Therapeutics's Stock Price Today?
A single share of KYMR can be purchased today for 45.40 -
What Is Kymera Therapeutics’s Stock Symbol?
Kymera Therapeutics trades on the nasdaq under the ticker symbol: KYMR -
When Is Kymera Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Kymera Therapeutics is scheduled on November 1, 2024 -
When Is KYMR's next ex-dividend date?
Kymera Therapeutics's next ex-dividend date is September 7, 2024 -
How To Buy Kymera Therapeutics Stock?
You can buy Kymera Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Kymera Therapeutics Competitors
-
Who Are Kymera Therapeutics's Competitors?
Below is a list of companies who compete with Kymera Therapeutics or are related in some way:
Kymera Therapeutics Dividend Yield
-
What Is KYMR Dividend Yield?
Kymera Therapeutics’s dividend yield currently is 0% -
What Is Kymera Therapeutics’s Payout Ratio?
Kymera Therapeutics’s payout ratio is 0% -
When Did Kymera Therapeutics Last Pay A Dividend?
The latest dividend pay date is September 7, 2024 -
What Is Kymera Therapeutics’s Dividend Per Share?
Kymera Therapeutics pays a dividend of $0.00 per share
Kymera Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 12.01% |
| Revenue: | 55.33% | 104.31% |
Analyst Recommendations
| Buy Recommendations: | 9 |
|---|---|
| Hold Recommendations: | 5 |
| Sell Recommendations: | 0 |
| Price Target: | 53.69 |
| Upside from Last Price: | 18.25% |